Bladder Cancer Photodynamic Therapeutic Agent with Off-On Magnetic Resonance Imaging Enhancement

Chen Xie; Ho Fai Chau; Jing Xiang Zhang; Sheng Tong; Lijun Jiang; Wan Yiu Fok; Hong Lok Lung; Shuai Zha; Rui Zou; Ju Jiao; Chi Fai Ng; Ping'an Ma; Junhui Zhang; Jun Lin; Kwok Keung Shiu; Jean Claude G. Bünzli; Wai Kwok Wong; Nicholas J. Long; Ga Lai Law; Ka Leung Wong

doi:10.1002/adtp.201900068

Bladder Cancer Photodynamic Therapeutic Agent with Off-On Magnetic Resonance Imaging Enhancement

Chen Xie, Ho Fai Chau, Jing Xiang Zhang, Sheng Tong, Lijun Jiang, Wan Yiu Fok, Hong Lok Lung, Shuai Zha, Rui Zou, Ju Jiao, Chi Fai Ng, Ping'an Ma, Junhui Zhang, Jun Lin, Kwok Keung Shiu, Jean Claude G. Bünzli, Wai Kwok Wong, Nicholas J. Long^*, Ga Lai Law^*, Ka Leung Wong^*

^*Corresponding author for this work

Research output: Contribution to journal › Journal article › peer-review

22 Citations (Scopus)

Abstract

Acting as an extracellular matrix protein receptor, α_Vβ₃ integrin becomes an appealing target for photodynamic therapy of bladder cancer. Here, specific α_Vβ₃-integrin-targeting porphyrinato-gadolinium complexes (Gd-PEG-Rⁿ) are demonstrated as off-on theranostic agents, where Rⁿ are specific peptides. Among them, Gd-PEG-R³ shows both impressive phototherapeutic index and robust in vivo magnetic resonance imaging (MRI) signal enhancement. Significant selectivity of Gd-PEG-R³ is proven by its high α_Vβ₃ integrin binding affinity in positive bladder cancer cells. All these findings support Gd-PEG-R³ as a promising bi-functional medical agent with both MRI contrasting ability and photodynamic therapeutic potential for curing bladder cancer.

Original language	English
Article number	1900068
Number of pages	7
Journal	Advanced Therapeutics
Volume	2
Issue number	11
Early online date	16 Jun 2019
DOIs	https://doi.org/10.1002/adtp.201900068
Publication status	Published - Nov 2019

User-Defined Keywords

bladder cancer
lanthanide
magnetic resonance imaging
photodynamic therapy
porphyrin

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/adtp.201900068

Cite this

Xie, C., Chau, H. F., Zhang, J. X., Tong, S., Jiang, L., Fok, W. Y., Lung, H. L., Zha, S., Zou, R., Jiao, J., Ng, C. F., Ma, P., Zhang, J., Lin, J., Shiu, K. K., Bünzli, J. C. G., Wong, W. K., Long, N. J., Law, G. L., & Wong, K. L. (2019). Bladder Cancer Photodynamic Therapeutic Agent with Off-On Magnetic Resonance Imaging Enhancement. Advanced Therapeutics, 2(11), Article 1900068. https://doi.org/10.1002/adtp.201900068

@article{4ef1646f9d86401ab704ef499c115bd5,

title = "Bladder Cancer Photodynamic Therapeutic Agent with Off-On Magnetic Resonance Imaging Enhancement",

abstract = "Acting as an extracellular matrix protein receptor, αVβ3 integrin becomes an appealing target for photodynamic therapy of bladder cancer. Here, specific αVβ3-integrin-targeting porphyrinato-gadolinium complexes (Gd-PEG-Rn) are demonstrated as off-on theranostic agents, where Rn are specific peptides. Among them, Gd-PEG-R3 shows both impressive phototherapeutic index and robust in vivo magnetic resonance imaging (MRI) signal enhancement. Significant selectivity of Gd-PEG-R3 is proven by its high αVβ3 integrin binding affinity in positive bladder cancer cells. All these findings support Gd-PEG-R3 as a promising bi-functional medical agent with both MRI contrasting ability and photodynamic therapeutic potential for curing bladder cancer.",

keywords = "bladder cancer, lanthanide, magnetic resonance imaging, photodynamic therapy, porphyrin",

author = "Chen Xie and Chau, {Ho Fai} and Zhang, {Jing Xiang} and Sheng Tong and Lijun Jiang and Fok, {Wan Yiu} and Lung, {Hong Lok} and Shuai Zha and Rui Zou and Ju Jiao and Ng, {Chi Fai} and Ping'an Ma and Junhui Zhang and Jun Lin and Shiu, {Kwok Keung} and B{\"u}nzli, {Jean Claude G.} and Wong, {Wai Kwok} and Long, {Nicholas J.} and Law, {Ga Lai} and Wong, {Ka Leung}",

note = "Funding Information: C.X. and H.-F.C. contributed equally to this work. This work was supported by grants from The Hong Kong Research Grant Council (HKBU12309516), the Hong Kong Baptist University (RC-ICRS/16-17/02-CHEM), CAS Croucher joint lab (CA18204), The Hong Kong Polytechnic University [Univeristy Research Facility for Chemical and Environmental Analysis (UCEA)]and The University Research Facility in Life Sciences (ULS), and The Hong Kong Research Grant Council PolyU 153013/17P and PolyU 153103/16P, also by the assistance from the Imperial College London. Publisher Copyright: {\textcopyright} 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim",

year = "2019",

month = nov,

doi = "10.1002/adtp.201900068",

language = "English",

volume = "2",

journal = "Advanced Therapeutics",

issn = "2366-3987",

publisher = "Wiley-Blackwell Publishing Ltd",

number = "11",

}

Xie, C, Chau, HF, Zhang, JX, Tong, S, Jiang, L, Fok, WY, Lung, HL, Zha, S, Zou, R, Jiao, J, Ng, CF, Ma, P, Zhang, J, Lin, J, Shiu, KK, Bünzli, JCG, Wong, WK, Long, NJ, Law, GL & Wong, KL 2019, 'Bladder Cancer Photodynamic Therapeutic Agent with Off-On Magnetic Resonance Imaging Enhancement', Advanced Therapeutics, vol. 2, no. 11, 1900068. https://doi.org/10.1002/adtp.201900068

TY - JOUR

T1 - Bladder Cancer Photodynamic Therapeutic Agent with Off-On Magnetic Resonance Imaging Enhancement

AU - Xie, Chen

AU - Chau, Ho Fai

AU - Zhang, Jing Xiang

AU - Tong, Sheng

AU - Jiang, Lijun

AU - Fok, Wan Yiu

AU - Lung, Hong Lok

AU - Zha, Shuai

AU - Zou, Rui

AU - Jiao, Ju

AU - Ng, Chi Fai

AU - Ma, Ping'an

AU - Zhang, Junhui

AU - Lin, Jun

AU - Shiu, Kwok Keung

AU - Bünzli, Jean Claude G.

AU - Wong, Wai Kwok

AU - Long, Nicholas J.

AU - Law, Ga Lai

AU - Wong, Ka Leung

N1 - Funding Information: C.X. and H.-F.C. contributed equally to this work. This work was supported by grants from The Hong Kong Research Grant Council (HKBU12309516), the Hong Kong Baptist University (RC-ICRS/16-17/02-CHEM), CAS Croucher joint lab (CA18204), The Hong Kong Polytechnic University [Univeristy Research Facility for Chemical and Environmental Analysis (UCEA)]and The University Research Facility in Life Sciences (ULS), and The Hong Kong Research Grant Council PolyU 153013/17P and PolyU 153103/16P, also by the assistance from the Imperial College London. Publisher Copyright: © 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim

PY - 2019/11

Y1 - 2019/11

N2 - Acting as an extracellular matrix protein receptor, αVβ3 integrin becomes an appealing target for photodynamic therapy of bladder cancer. Here, specific αVβ3-integrin-targeting porphyrinato-gadolinium complexes (Gd-PEG-Rn) are demonstrated as off-on theranostic agents, where Rn are specific peptides. Among them, Gd-PEG-R3 shows both impressive phototherapeutic index and robust in vivo magnetic resonance imaging (MRI) signal enhancement. Significant selectivity of Gd-PEG-R3 is proven by its high αVβ3 integrin binding affinity in positive bladder cancer cells. All these findings support Gd-PEG-R3 as a promising bi-functional medical agent with both MRI contrasting ability and photodynamic therapeutic potential for curing bladder cancer.

AB - Acting as an extracellular matrix protein receptor, αVβ3 integrin becomes an appealing target for photodynamic therapy of bladder cancer. Here, specific αVβ3-integrin-targeting porphyrinato-gadolinium complexes (Gd-PEG-Rn) are demonstrated as off-on theranostic agents, where Rn are specific peptides. Among them, Gd-PEG-R3 shows both impressive phototherapeutic index and robust in vivo magnetic resonance imaging (MRI) signal enhancement. Significant selectivity of Gd-PEG-R3 is proven by its high αVβ3 integrin binding affinity in positive bladder cancer cells. All these findings support Gd-PEG-R3 as a promising bi-functional medical agent with both MRI contrasting ability and photodynamic therapeutic potential for curing bladder cancer.

KW - bladder cancer

KW - lanthanide

KW - magnetic resonance imaging

KW - photodynamic therapy

KW - porphyrin

UR - http://www.scopus.com/inward/record.url?scp=85080976482&partnerID=8YFLogxK

U2 - 10.1002/adtp.201900068

DO - 10.1002/adtp.201900068

M3 - Journal article

AN - SCOPUS:85080976482

SN - 2366-3987

VL - 2

JO - Advanced Therapeutics

JF - Advanced Therapeutics

IS - 11

M1 - 1900068

ER -

Bladder Cancer Photodynamic Therapeutic Agent with Off-On Magnetic Resonance Imaging Enhancement

Abstract

User-Defined Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this